Skip to main content
    I

    IO Biotech Inc (IOBT)

    Official site

    BIOTECHNOLOGY

    $0.05
    +0.00 (+0.00%)

    Last updated: Apr 07, 2026 at 5:00 PM ET

    IO Biotech Inc (IOBT) Financials: Revenue, Profit and Cash Flow

    Updated Nov 7, 2025. Financial statements from company filings, amounts in US dollars.

    IO Biotech reported revenue of $0 for the fiscal year ended Dec 31, 2024. That year, net income was -$95.49M, operating cash flow was -$82.35M and free cash flow was -$82.39M. The quarter ended Sep 30, 2025 had revenue of $0 and net income of -$8.38M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2024, with an operating loss of $95.18M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2019 to Dec 2024

    Income Statement

    In the fiscal year ended Dec 2024, the net loss widened from the year before. In the quarter ended Sep 2025, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Cost of revenue$849.00K$756.00K$540.00KN/AN/AN/A
    Gross profit-$849.00K-$756.00K-$540.00KN/AN/AN/A
    Research and development$71.48M$67.83M$46.99M$30.15M$8.46M$7.94M
    Operating income-$95.18M-$91.44M-$71.42M-$41.23M-$10.14M-$9.91M
    Net income-$95.49M-$86.08M-$71.46M-$67.88M-$12.04M-$10.75M
    EBITDA-$93.20M-$84.47M-$69.34MN/AN/A-$824.00K
    Fiscal years ended Dec 2019 to Dec 2024

    Quarterly

    Line itemSep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022
    Revenue$0$0$0$850.00K$0$0$0$1.11M$0$0$0$0
    Gross profit-$230.00K-$234.00K-$227.00K-$219.00K-$205.00K-$214.00K-$211.00K-$201.00K-$194.00K-$187.00K-$174.00K-$190.00K
    Operating income-$19.36M-$23.17M-$22.58M-$26.94M-$26.50M-$21.53M-$20.20M-$28.18M-$23.48M-$21.85M-$17.92M-$20.39M
    Net income-$8.38M-$26.22M-$22.42M-$31.33M-$24.02M-$20.69M-$19.46M-$26.18M-$21.68M-$21.18M-$17.04M-$20.07M
    Last 12 quarters

    Balance Sheet

    As of Dec 2024, cash and equivalents exceeded short-term debt of $717.00K by $59.31M.

    Annual

    Line itemDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Total assets$67.70M$150.72M$151.81M$222.29M$5.65M$9.42M
    Current assets$64.95M$147.25M$148.22M$221.74M$5.63M$9.40M
    Cash and equivalents$60.03M$143.19M$142.59M$211.53M$3.40M$7.85M
    Total liabilities$20.68M$17.56M$12.95M$10.36M$3.05M$10.89M
    Short-term debt$717.00K$655.00K$515.00KN/AN/A$8.66M
    Shareholder equity$47.02M$133.16M$138.85M$211.92M$2.60M-$1.47M
    Fiscal years ended Dec 2019 to Dec 2024

    Quarterly

    Line itemSep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022
    Total assets$39.96M$42.33M$45.74M$67.70M$89.94M$111.47M$128.16M$150.72M$172.55M$117.56M$136.84M$151.81M
    Total liabilities$39.05M$40.73M$19.31M$20.68M$17.38M$15.20M$12.69M$17.56M$14.96M$13.04M$12.63M$12.95M
    Cash and equivalents$30.66M$28.13M$37.09M$60.03M$80.19M$100.75M$117.98M$143.19M$165.50M$110.09M$128.53M$142.59M
    Shareholder equity$911.00K$1.59M$26.42M$47.02M$72.56M$96.27M$115.47M$133.16M$157.59M$104.52M$124.22M$138.85M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2024.

    Annual

    Line itemDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Operating cash flow-$82.35M-$71.74M-$59.73M-$40.65M-$9.96M-$8.89M
    Capital expenditures$44.00K$323.00K$690.00K$153.00K$153.00K$153.00K
    Free cash flow-$82.39M-$72.06M-$60.42M-$40.80M-$10.11M-$9.04M
    Investing cash flow-$44.00K-$323.00K-$690.00K-$153.00K-$153.00K-$153.00K
    Financing cash flow$0$71.86M$187.54M$252.95M$5.10M$9.01M
    Fiscal years ended Dec 2019 to Dec 2024

    Quarterly

    Line itemSep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022
    Operating cash flow-$18.48M-$19.82M-$23.07M-$19.63M-$20.81M-$16.98M-$24.93M-$22.80M-$15.99M-$18.26M-$14.69M-$12.53M
    Capital expenditures$4.00K$26.00K$28.00K$11.00K$10.00K$12.00K$11.00K$112.00K$24.00K$39.00K$148.00K$349.00K
    Free cash flow-$18.48M-$19.85M-$23.10M-$19.64M-$20.82M-$16.99M-$24.94M-$22.91M-$16.01M-$18.30M-$14.84M-$12.88M
    Last 12 quarters

    Frequently Asked Questions About IOBT

    What is IO Biotech's annual revenue?

    IO Biotech reported revenue of $0 for the fiscal year ended Dec 31, 2024.

    Is IO Biotech profitable?

    No. IO Biotech reported net income of -$95.49M for the fiscal year ended Dec 31, 2024.

    How much free cash flow does IOBT generate?

    For the fiscal year ended Dec 31, 2024, operating cash flow of -$82.35M minus capital expenditures of $44.00K produced free cash flow of -$82.39M.

    How much debt does IO Biotech have?

    The balance sheet dated Dec 31, 2024 reported short-term debt of $717.00K and cash and equivalents of $60.03M.